Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

Program Description

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn disease (CD), is characterized by chronic inflammation of the gastrointestinal tract. Patients with IBD often experience debilitating symptoms that contribute to significant clinical and economic burden. Clinical trial data have underscored the importance of objective endoscopic endpoints in determining long-term IBD control, but patients often experience barriers to care and suboptimal treatment outcomes. These limitations have driven the development of IL-23 inhibitors, which offer a targeted approach by selectively blocking the IL-23 pathway, a key driver of inflammation in IBD. This program will explore safety and efficacy data of IL-23 inhibitors, with a focus on their dosing flexibility and intravenous to subcutaneous administration transitions. The importance of a multidisciplinary care approach in IBD to address treatment access barriers will be highlighted. The discussion will also cover the economic impact of suboptimal therapy, cost-effective care strategies, and how specialty and managed care pharmacists can positively affect health care resource utilization.

Target audience: Managed Care Pharmacist, Specialty Pharmacist

Type of activity: Application
Release date: May 30, 2025
Expiration date: June 1, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Point out the current challenges in inflammatory bowel disease (IBD) management, including the limitations of existing therapies and the clinical burden
• Analyze the role of IL-23 inhibitors and the clinical data supporting their use in the management of ulcerative colitis and Crohn disease
• Identify strategies for integrating IL-23 inhibitors into patient-centered treatment plans for IBD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-165-H01-P.The activity is available for CE credit through June 1, 2026

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

David Choi, PharmD, BCACP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Bristol Myers Squibb, Boehringer Ingelheim, AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals, Pfizer; Speakers Bureau: Janssen Pharmaceuticals, AbbVie, Eli Lilly and Company

Faculty

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Victoria Chirdo; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms